Daunorubicin/cytarabine

< Daunorubicin

Daunorubicin/cytarabine
Cytarabine
Daunorubicin
Combination of
DaunorubicinAnthracycline
CytarabineAntimetabolite
Clinical data
Trade namesVyxeos
Other namesCPX-351
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU: D
Routes of
administration		Intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Daunorubicin/cytarabine, sold under the brand name Vyxeos, is a fixed-dose combination medication used for the treatment of acute myeloid leukemia. It contains the liposomal bound daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.